Dolfenex

Quick links to important sections

Dolfenex

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolfenex

Property Description
Active ingredient Diclofenac (often as Diclofenac sodium)
Forms Tablets, suppositories, gel, solution, ampoules
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Relief of pain and reduction of inflammation
Origin Synthetic compound

What is Dolfenex and Its Pharmacological Class?

Dolfenex is the product name for a medicine containing the active ingredient Diclofenac, which is typically administered as Diclofenac sodium. This synthetic compound is definitively classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its core identity is that of an analgesic and anti-rheumatic agent used to provide relief from discomfort.

The NSAID classification places Diclofenac within a group of medicines whose efficacy is clinically recognized for targeting the biological processes of the inflammatory cascade. This pharmacological action ensures Dolfenex's purpose is to intervene directly in discomfort and inflammation pathways, achieving both an anti-pain (analgesic) and anti-swelling (anti-inflammatory) effect. Diclofenac has an established efficacy in the treatment of pain and inflammatory conditions. This confirms that the drug is reliably effective at easing discomfort and reducing physical signs of inflammation.

Dolfenex Composition and Available Forms

The core of Dolfenex is the single-ingredient product Diclofenac, serving as the sole pharmacologically active substance. This compound is formulated with various pharmaceutical excipients and a specific base/vehicle material depending on the application. The availability of diverse dosage form(s) ensures the medicine can be delivered effectively through several routes of administration, allowing precise targeting of discomfort.

The pharmaceutical preparations include tablets for oral intake and suppositories for rectal administration. Diclofenac is also commonly prepared as topical preparations, such as a gel or a cutaneous solution, designed for topical/cutaneous administration. This emphasizes the importance of the correct dosage form for targeting discomfort either locally or throughout the body. Unlike some simple analgesics, the breadth of Dolfenex's formulation allows it to address conditions, such as musculoskeletal disorders, requiring both systemic and localized approaches.

General Therapeutic Purpose of Diclofenac

The overall purpose of Diclofenac is to diminish physical discomfort and reduce swelling by modulating the body’s inflammatory reaction. This general benefit is achieved through its primary mechanism of effect: the inhibition of the prostaglandin synthesis pathway. This specific physiological action means the drug provides both an effective pain relief and actively mitigates the core symptoms of inflammation concurrently. By limiting the production of these chemical messengers, Dolfenex addresses the underlying biological signaling that contributes to prolonged discomfort and swelling.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Dolfenex?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety constraints for the active ingredient Diclofenac (Dolfenex), an Non-Steroidal Anti-Inflammatory Drug (NSAID), as described in authoritative government regulatory documents.


Official Adverse Reactions by Frequency and Organ System

Adverse reactions are classified by frequency, with common effects primarily impacting the gastrointestinal and nervous systems:

Frequency Category Primary Adverse Reactions
Common Abdominal pain, Nausea, Vomiting, Diarrhea, Dyspepsia, Headache, Dizziness, Elevated liver enzymes (ALT/AST).
Rare Gastrointestinal bleeding, Ulceration, Hepatitis, Hypersensitivity reactions (e.g., Anaphylaxis), Urticaria.
Very Rare Myocardial Infarction, Stroke, Heart Failure, Acute Renal Failure, Liver Failure, Severe skin reactions (SJS, TEN).

Serious Regulatory Safety Statements

Official labeling emphasizes serious risks, with warnings regarding potentially fatal adverse events:

  • Serious Gastrointestinal Risks: Inflammation, bleeding, ulceration, and perforation of the stomach or intestines. These can occur at any time during treatment, with or without warning symptoms.
  • Serious Cardiovascular Risks: Increased risk of serious cardiovascular thrombotic events, including Myocardial Infarction and Stroke. This risk may increase with duration of use and at higher doses.

Population-Specific and Use Constraints

Specific restrictions are defined in regulatory documents for certain patient groups and clinical contexts:

  • Elderly Patients: Have an increased risk of serious gastrointestinal events.
  • Pregnancy: Use is contraindicated in the third trimester.
  • Contraindications: Use is restricted in patients with established severe heart failure (NYHA II–IV), pre-existing severe hepatic or renal failure, or those undergoing Coronary Artery Bypass Graft (CABG) surgery.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines the specific manifestations and required emergency actions for a Diclofenac (Dolfenex) overdose. All suspected or confirmed cases require immediate medical attention, as mandated by regulatory authorities, and hospital monitoring is required to manage potentially severe outcomes

.

Documented Overdose Manifestations

Overdose may present with gastrointestinal effects such as nausea, vomiting, epigastric pain, and documented GI bleeding. Central Nervous System (CNS) effects include headache, drowsiness, lethargy, disorientation, tinnitus, and occasional convulsions. Physiological signs noted in labels include oliguria (reduced urine output).

Severe Outcomes and Management

Life-threatening outcomes documented in official labeling include acute renal failure, significant liver damage (including potential fulminant hepatitis), severe Gl hemorrhage, and metabolic acidosis. Due to these risks, patients with pre-existing renal or hepatic impairment face increased toxicity, and children face an increased risk of CNS effects.

Management is restricted to symptomatic and supportive treatment, including gastric decontamination measures like activated charcoal. Official labeling confirms that no specific antidote is known for Diclofenac, making close medical supervision and monitoring of vital signs and organ function (renal and hepatic) mandatory.

Therapeutic Uses of Dolfenex

Dolfenex (Diclofenac) may be part of symptomatic management, relevant in contexts marked by increased discomfort or tension, and helps manage symptoms related to physical discomfort, inflammation, and stiffness. The medication may assist with easing symptoms related to inflammatory or irritative states across several key therapeutic areas.

It is commonly used across conditions characterized by periods of heightened symptoms, and may be applied in scenarios where additional management of discomfort is required for specific manifestations like migraine attacks or symptoms associated with acute episodes such as sprains. This includes symptoms that interfere with daily functioning in conditions like Osteoarthritis and Rheumatoid Arthritis. Dolfenex is applied in clinical settings that involve acute or unstable symptom patterns, which supports the patient during difficult episodes by easing distress.

The medication offers supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load.

“The medication offers supportive relief when symptoms interfere with routine activities.”

Quick Fact: Symptomatic Support for Pain and Stiffness

Dolfenex generally contributes to easing the overall symptom load, which supports patients during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Dolfenex (Diclofenac) eligibility is strictly defined by regulatory authorities based on a patient’s health profile and age. Use is Contraindicated in several population groups. This includes individuals with a documented hypersensitivity to Diclofenac or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and patients with active gastrointestinal ulceration, bleeding, or perforation. Absolute prohibitions also apply to patients with severe hepatic or renal impairment (kidney or liver failure) and those with established severe heart disease such as Congestive Heart Failure (NYHA Class II-IV), Ischemic Heart Disease, or Cerebrovascular Disease. Dolfenex is contraindicated during the last trimester of pregnancy and for the management of pain following Coronary Artery Bypass Graft (CABG) surgery.


Age-Related and Conditional Use

  • Adults are the primary eligible population. Use in adolescents is generally restricted to those 12 years of age and older for specific formulations, and high-strength systemic forms are not suitable for individuals under 18.
  • Conditional Use is required for the elderly, who must be closely monitored. Caution is also necessary for patients with mild to moderate kidney or liver impairment and those with significant cardiovascular risk factors (e.g., hypertension, diabetes).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Dolfenex (Diclofenac) with certain medicinal products and substances. Use of Dolfenex is contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is generally avoided due to the increased potential for additive gastrointestinal side effects.

Documented Pharmacokinetic and Exposure Effects

Diclofenac may increase the serum concentration of co-administered drugs like Lithium and Methotrexate by reducing their clearance. A potent CYP enzyme inhibitor, Voriconazole, is documented to significantly increase Diclofenac’s systemic exposure. Co-administration with Digoxin or Cyclosporine also necessitates caution due to potential increases in their respective serum concentrations or heightened risk of nephrotoxicity.

Pharmacodynamic Risks and Restrictions

This drug is documented to augment the risk of serious bleeding when taken with agents such as Anticoagulants, Antiplatelet agents, and SSRIs. It may also diminish the antihypertensive effect of medicines like ACE Inhibitors, ARBs, and Diuretics, and co-use carries an increased risk of renal impairment, particularly in the elderly. A mandatory timing rule requires separation from Mifepristone by 8 to 12 days.

Mechanism of Action

Inhibition of Prostaglandin Synthesis

This mechanism describes how Dolfenex works primarily by acting as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This interference with the Arachidonic Acid Cascade prevents the conversion of precursor molecules into prostaglandins, which are key chemical mediators. This targeted molecular action reduces the overall level of these mediators in the body.


Modulation of Localized Physiological Responses

By reducing the amount of prostaglandins, the drug engages mechanisms that influence peripheral nervous system signaling and localized vascular systems. This directly affects the sensitivity of nociceptors (pain-sensing nerves) and restricts the mediators that promote vasodilation (blood vessel widening) and capillary leakage. This physiological effect results in an altered signaling dynamic within targeted pathways, leading to a dampening of overactive local responses.

Dosage and Administration Information

Dolfenex (Diclofenac) is used according to specific administration routes and dosage protocols outlined in official prescribing information.

Official Routes and Dose Ranges

The medicine is approved for oral (tablets, solution), topical (gel), rectal (suppositories), and parenteral (intramuscular and intravenous infusion) administration. Standard adult oral dosing typically ranges from 100 mg to 150 mg daily, administered in divided doses. The general maximum daily dose is 150 mg. For parenteral use, a single 75 mg dose may be repeated, but such use is restricted to a maximum of two consecutive days. Topical gel is typically applied four times daily, with the dose measured using a supplied dosing card.

Administration Requirements and Timing

Specific rules govern the method of intake. Delayed-release tablets must be swallowed whole and are generally taken with or immediately after food. Conversely, the powder for oral solution is to be mixed with water and consumed immediately, as taking this form with food may reduce the rate of absorption. Intravenous administration is strictly limited to an infusion after dilution and buffering and must not be administered as a bolus injection.

Duration and Population Rules

The official instructions mandate that treatment must utilize the lowest effective dosage for the shortest duration possible. Older adults are advised to adhere to this principle rigorously. Treatment protocols require periodic re-evaluation for patients receiving long-term oral therapy to determine the need for continued symptomatic use.

Recent Clinical Evidence

Dolfenex: Recent Clinical Evidence

Evidence for Use in Chronic Joint and Inflammatory Conditions

The research base for Dolfenex in the context of research exploring symptoms related to chronic conditions like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS) primarily consists of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Studies monitored patient-reported outcomes describing perceived discomfort, such as scores on physical function scales and changes in reported pain intensity and joint stiffness over defined time intervals. Findings describe patterns observed in the studies when the medicine was compared against a control (like a placebo). Data show patterns related to measured change in pain scores and functional ability, often reported over an intermediate duration, typically up to 12 weeks. Outcomes measured beyond the one-year mark are not fully established.


Research on Acute Pain and Short-Term Symptom Management

Evidence for this application relies primarily on short-term Randomized Controlled Trials and their associated systematic reviews, which often observe patterns over defined time intervals immediately following administration. This evidence describes research examining the application for acute injuries and other defined acute pain states. The studies explored the speed and magnitude of patient-reported outcomes related to physical discomfort. Findings describe patterns observed in the studies related to how quickly a patient reported a change in symptom intensity. Research highlights changes measured during the study period, showing the pattern of relief for short-term, temporary physiological imbalance. There is limited information for long-term outcomes regarding the utility of the medicine’s use beyond the immediate acute phase (typically more than two weeks).


Evidence in Specific Patient Populations and Research Gaps

Most evidence that examines how symptoms evolve in the observed populations for Dolfenex is derived from follow-up durations that are classified as short or intermediate. The research has included a focus on certain populations: Dolfenex was evaluated in Older Adults, a population whose symptoms related to chronic conditions were the focus of several studies. Studies also explored the use of Dolfenex in Adolescents (typically age 12 and older) in research relevant in trials assessing short-term or episodic symptom patterns. However, results apply only to the populations studied. Data for the youngest patients (children under 12) remains insufficient across many regulatory dossiers. Studies help show what has been observed so far in group patterns, but research provides context but not individual predictions.

Key Studies & References Label: DICLOFENAC SODIUM tablet, delayed release - DailyMed (FDA Monograph)

Frequently Asked Questions (FAQ)

Common questions about Dolfenex (FAQ)


Q: How quickly does Dolfenex start working?

Official information indicates that for immediate-release forms of Dolfenex, the maximum concentration of the medicine in the blood is typically reached within 2 to 3 hours after intake. However, it is noted that the experience of pain relief may begin sooner than this peak concentration. The rate at which the medicine is absorbed can also depend on the specific type of formulation, such as a tablet versus a powder for oral solution.

Q: How long does Dolfenex stay in your system?

Regulatory documents describe the active component of Dolfenex as having a short terminal half-life, which means the body quickly processes and eliminates the unchanged medicine within approximately 1 to 2 hours. This indicates a rapid rate of clearance for the unchanged, active medicine. However, its inactive metabolites, or breakdown products, may remain in the system for a longer duration.

Q: Is Dolfenex safe for older people (seniors)?

Official instructions state that older adults may face an increased risk of experiencing serious side effects, specifically gastrointestinal bleeding and cardiovascular events. To help mitigate these risks, regulatory guidance requires that the lowest effective dose be utilized for the shortest duration possible, and close monitoring is mandated during the course of treatment for this population.

Q: What kind of research evidence supports the use of Dolfenex?

The understanding of Dolfenex's therapeutic profile for conditions like arthritis and acute pain is supported primarily by evidence gathered from randomized controlled trials (RCTs) and systematic reviews, which assess patient-reported outcomes like changes in pain intensity and physical function.

Q: Is it normal to feel a bit dizzy after starting Dolfenex?

Yes, dizziness is listed in official product information as a common side effect of Dolfenex. Because this medicine can affect balance, regulatory warnings state that caution is necessary when driving or operating machinery if dizziness is experienced.

Q: Does Dolfenex cause drowsiness or affect driving?

Regulatory warnings indicate that Dolfenex can potentially cause side effects such as dizziness, vertigo, or visual disturbances. Official warnings state that driving or operating complex machinery should be avoided if these effects are experienced.

Q: Is Dolfenex addictive?

No, official classifications confirm that Dolfenex (Diclofenac) is defined as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not categorized as a controlled substance and does not carry the potential for abuse.

Q: Why does the Dolfenex patient leaflet mention alcohol?

Official medical information advises avoiding the consumption of alcohol while using this medication. This guidance is in place because combining Dolfenex with alcohol may increase the risk of serious side effects impacting the stomach and intestines, including the risk of bleeding.

Q: Is Dolfenex used for chronic pain or only acute issues?

Dolfenex is approved for managing symptoms associated with both acute pain conditions, such as short-term injuries, and chronic inflammatory conditions, including osteoarthritis and rheumatoid arthritis.

Q: What is the typical time frame for the therapeutic effect of Dolfenex?

The medicine is noted for its rapid elimination from the body, with a terminal half-life of 1 to 2 hours. This short duration indicates that the concentration of the active drug decreases rapidly after it is absorbed and has been distributed throughout the body.

Q: Are there any food restrictions when taking Dolfenex?

Taking Dolfenex with food generally does not significantly change the total amount of medicine absorbed into the body. However, official sources note that consuming the medicine alongside food may slow down the rate of absorption and, consequently, slightly delay the onset of its intended action.

Q: Can Dolfenex be taken on an empty stomach?

While the medicine can be taken without food, delayed-release tablets are generally advised to be taken with or immediately after food to help reduce the risk of stomach irritation. Official information also notes that taking certain forms, like the oral solution powder, with food may reduce the speed of absorption.

Q: Has Dolfenex been studied in children?

Use of Dolfenex is typically restricted to adolescents aged 12 years and older for specific formulations. Regulatory dossiers indicate that data for the youngest patients, those under 12, remains insufficient, limiting the use of the medicine in that age group.

Q: Is Dolfenex available without a prescription in some countries?

The legal status of Dolfenex varies across different countries and regions. While high-strength and systemic forms (tablets, injections) are often available by prescription only, lower-strength topical gels or certain tablets may be designated as over-the-counter in certain jurisdictions.

Q: What happens if I miss a dose of Dolfenex?

Official information generally advises that if a dose is missed, it should be taken as soon as the patient remembers. If it is close to the time for the next scheduled dose, the missed dose is typically skipped, and the regular schedule is resumed. Regulatory advice cautions against taking two doses at the same time to compensate for a missed one.

Q: Does Dolfenex affect fertility in men or women?

Official regulatory documents indicate that the use of Dolfenex may potentially impair female fertility. For women experiencing difficulty becoming pregnant or undergoing investigation for infertility, official regulatory recommendations include considering the discontinuation of the medicine.

Q: Does Dolfenex thin your blood?

Dolfenex is not classified as a standard 'blood thinner,' but official warnings state that it can affect platelet function. Because of this, it may cause an increased risk of serious bleeding. It is also restricted for use in patients who have active gastrointestinal bleeding.

Q: What is the shelf life or expiry of Dolfenex?

The definitive shelf life and expiration date for Dolfenex are printed directly on the product's outer packaging and carton. Official instructions advise that the medicine must not be used after this expiration date has passed.

Q: Are there any long-term safety concerns with Dolfenex?

Official labeling emphasizes that long-term use is associated with serious risks, including an increased risk of cardiovascular thrombotic events (such as heart attack and stroke) and gastrointestinal risks (such as bleeding and ulcers). Official guidelines require the use of the lowest effective dose for the shortest duration possible.

Q: Can Dolfenex be crushed or split?

Regulatory guidance specifies that certain forms, such as delayed-release and extended-release tablets, must be swallowed whole. These formulations should not be crushed, split, or chewed, as doing so can damage the enteric coating and lead to stomach irritation or change how the medicine is absorbed.

Q: Does Dolfenex affect sleep?

While the effect is not classified as common, official adverse reaction reports list sleep disturbances, which include both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness), as possible side effects associated with Dolfenex.

Q: What is the general recommended length of treatment with Dolfenex?

Official warnings emphasize that treatment should always utilize the lowest effective dosage for the shortest duration possible to manage symptoms. For patients using the medicine for long-term chronic conditions, the need for continued therapy must be periodically re-evaluated by a healthcare professional.

Q: Are allergic reactions to Dolfenex common?

According to official frequency classifications, allergic reactions (hypersensitivity) to Dolfenex are considered rare. However, severe, potentially fatal anaphylactic reactions have been reported very rarely in official safety documents.

Q: Can Dolfenex cause changes in mood or anxiety?

Official adverse reaction reports categorize psychiatric disturbances, including depression, anxiety, and irritability, as uncommon or rare side effects. These effects are listed in regulatory documents as possible reactions associated with the medicine.

Q: Does taking Dolfenex increase sensitivity to the sun?

Yes, regulatory documents indicate that photosensitivity reactions, which are an increased sensitivity to sunlight, have been reported. Official warnings state that sun exposure should be avoided or minimized during the treatment period.

Q: Is Dolfenex safe to take with birth control pills?

Official interaction tables do not document that Dolfenex directly affects the effectiveness of hormonal contraceptives. However, if side effects like vomiting or severe diarrhea occur, these may potentially reduce the absorption of oral contraceptive pills.

Q: Are there official warnings about Dolfenex and mental health?

Official information lists psychiatric disturbances among the possible adverse reactions associated with Dolfenex. These reactions, which include depression, anxiety, and irritability, are classified as uncommon or rare effects.

Q: Can Dolfenex be taken with herbal supplements?

While specific herbal supplements may not be individually listed in official documents, Dolfenex can interact with agents that affect blood clotting, such as high doses of Vitamin E or certain herbals. Regulatory guidance suggests reviewing all herbal supplements with a healthcare provider before starting treatment.

Q: Why do doctors prescribe Dolfenex for certain types of headaches?

Dolfenex is a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is approved for managing specific acute pain conditions. Official indications include its use for certain types of headaches, such as migraines, due to its documented anti-inflammatory and pain-relieving properties.

How should Dolfenex be stored and disposed of?

How to Store and Dispose of Dolfenex

The official storage and disposal guidelines for Dolfenex (Diclofenac) are designed to maintain product quality and ensure safety, strictly following regulatory documentation.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing. Store away from heat, moisture, and direct light.
Container Store in the closed, original container.
Child Safety Must be kept out of the reach and sight of children, preferably in a dry, locked location.

Disposal Instructions

Unused or expired Dolfenex should be disposed of via a drug take-back program or mail-back envelope. If a take-back program is unavailable, mix the medicine with an undesirable substance, such as coffee grounds or dirt, seal the mixture in a bag, and discard it in the household trash. The medication must not be flushed down the toilet or poured down any drain, as this can lead to environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolfenex found in:

A-Z Index: